ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1122

Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review

Jove Graham1, Tonia Novosat1, Haiyan Sun1, Brian Piper2, Joseph Boscarino1, Melissa Kern1, Vanessa Duboski3, Eric Wright3, Patricia Schepman4, Rebecca Robinson5, Edward Casey6, Craig Beck7 and Jerry Hall8, 1Geisinger, Danville, 2Geisinger, Scranton, 3Geisinger, Forty Fort, 4Pfizer, New York City, NY, 5Eli Lilly and Company, Indianapolis, 6Pfizer, New York, 7Pfizer, London, 8Eli Lilly and Company, Indianapolis, IN

Meeting: ACR Convergence 2020

Keywords: Epidemiology, Osteoarthritis, Pharmacoepidemiology, population studies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Osteoarthritis – Clinical Poster I

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) is a mechanically and immunologically mediated common disease with a complex pathogenesis.  Despite epidemiologic studies proving increasing age, obesity and female gender as risk factors, many individuals are unable to manage OA symptoms and optimal treatment strategies at a population health level remain a challenge.  Our aim was to determine prevalence, incidence and characteristics of OA patients over an 18-year timeframe to provide insight into what treatments and preventative strategies would maximize impact.

Methods: This was a retrospective descriptive study reviewing electronic health records and billing data at Geisinger, an integrated health system in central and northeastern Pennsylvania serving over 500,000 patients per year.  Patients were included if they had at least two outpatient encounters at age 18 or greater and defined as having OA after having at least one diagnosis code for OA (ICD-9: 715.*, ICD-10 M15-19) on a problem list or encounter diagnosis or had an OA-related procedure (hip or knee replacement, arthroscopy or injection). Patients with total knee replacement (TKR) were also examined separately as a subset. For each year from 2001-2018, we calculated OA prevalence (percent of patients seen with OA) and incidence (percent of patients newly diagnosed with OA that year).  We also examined baseline demographics, OA-related prescription medication use, and comorbidities at any time during the study period.

Results: We identified 271,126 patients with encounters in the health system and evidence of OA, representing 32% of the total patient population in 2018.  Yearly incidence remained steady over the past 10 years at between 4 and 5 newly diagnosed per 100 and was similar between males and females.  The cohort remained steady at approximately 60% female, and consistent with the geographic region, was 98% Caucasian and non-Hispanic.  The largest segment of the OA population was in the range of 45 to 64 years old at first encounter, but the youngest age segment (18-45 years old) increased from 20% to 25% of the OA population over the study period.  Over half (54%) of OA patients had a BMI over 30 and this percentage increased by 7% since 2001.  Non-tramadol opioids were the most commonly prescribed pain medications, followed by acetaminophen (prescription or over-the-counter) and oral non-steroidal anti-inflammatory drugs.  Depression and anxiety disorders were diagnosed in 17% and 20% of the OA population, respectively, 20% reported chronic obstructive pulmonary disease, and 46% reported current or past tobacco smoking.  Approximately 4% of patients underwent TKR; this subgroup was more likely to use prescription pain medication and had higher rates of several chronic diseases including congestive heart failure, hypertension and chronic kidney disease.

Conclusion: Osteoarthritis affected a large, increasing segment of a large health system population, with higher rates among females and the proportion of younger individuals increasing over time.  The treatment of these patients may have been further complicated by comorbidities including obesity, depression, anxiety and multiple chronic disease states.

Demographics, Medications, and Comorbidities Table


Disclosure: J. Graham, None; T. Novosat, Pfizer, 2; H. Sun, None; B. Piper, Pfizer, 2, 9; J. Boscarino, None; M. Kern, None; V. Duboski, None; E. Wright, None; P. Schepman, Pfizer, 1, 2; R. Robinson, Eli Lilly and Company, 1, 3; E. Casey, Pfizer, Inc., 1, 3; C. Beck, Pfizer, 1, 2; J. Hall, Eli Lilly & Company, 1, 3.

To cite this abstract in AMA style:

Graham J, Novosat T, Sun H, Piper B, Boscarino J, Kern M, Duboski V, Wright E, Schepman P, Robinson R, Casey E, Beck C, Hall J. Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/osteoarthritis-in-a-large-integrated-health-system-population-18-year-retrospective-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoarthritis-in-a-large-integrated-health-system-population-18-year-retrospective-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology